ENDV (Endonovo Therapeutics) EBIT per Share : $-0.00 (TTM As of Sep. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Endonovo Therapeutics EBIT per Share?

Endonovo Therapeutics's EBIT per Share for the three months ended in Sep. 2024 was $0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.00.

During the past 3 years, the average EBIT per Share Growth Rate was 79.70% per year. During the past 5 years, the average EBIT per Share Growth Rate was 82.80% per year. During the past 10 years, the average EBIT per Share Growth Rate was 70.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Endonovo Therapeutics's EBIT per Share or its related term are showing as below:

ENDV' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 24.3 Med: 75.2 Max: 85.2
Current: 79.7

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Endonovo Therapeutics was 85.20% per year. The lowest was 24.30% per year. And the median was 75.20% per year.

ENDV's 3-Year EBIT Growth Rate is ranked better than
98.62% of 1235 companies
in the Biotechnology industry
Industry Median: 7.9 vs ENDV: 79.70

Endonovo Therapeutics's EBIT for the three months ended in Sep. 2024 was $-0.39 Mil.

Endonovo Therapeutics EBIT per Share Historical Data

The historical data trend for Endonovo Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endonovo Therapeutics EBIT per Share Chart

Endonovo Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-16.10

0.14

-0.04

-0.12

0.01

Endonovo Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24	Sep24
EBIT per Share	Get a 7-Day Free Trial															-	-	-	-	-

Endonovo Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Endonovo Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	8.207	/	1350.768
=	0.01

Endonovo Therapeutics's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

	EBIT per Share		(Q: Sep. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.388	/	1468.908
=	-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00

Endonovo Therapeutics (OTCPK:ENDV) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Endonovo Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Endonovo Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Endonovo Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Endonovo Therapeutics Inc (OTCPK:ENDV) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367

Website

https://www.endonovo.com

Endonovo Therapeutics Inc is an USA-based biotechnology company that focuses on the business of biomedical research and development, particularly in regenerative medicine, which has included the development of its proprietary square waveform device. It is engaged in developing the Immunotronics platform which is non-implantable, a non-invasive medical device to target inflammatory conditions in vital organs; and the Cytotronics platform which uses Time-Varying Electromagnetic Fields technology for the creation of cell-based therapies. The company generates its revenue through its technology licensing and commercialization activities.

Executives

Alan Brian Collier	director, 10 percent owner, officer: CEO	6320 CANOGA AVENUE, 15TH FLOOR, WOODLAND HILLS CA 91367
Michael Scott Mann	10 percent owner, officer: President	6320 CANOGA AVENUE, WOODLAND HILLS CA 91367